1610056-01-3
| 中文名称 | 1610056-01-3 |
|---|---|
| 中文同义词 | |
| 英文名称 | Peptide T TFA |
| 英文同义词 | Peptide T TFA;((2S)-2-((2S,3R)-2-((2S,3R)-2-((S)-2-((S)-2-aminopropanamido)-3-hydroxypropanamido)-3-hydroxybutanamido)-3-hydroxybutanamido)-3-hydroxybutanoyl)-L-asparaginyl-L-tyrosyl-L-threonine compound with 2,2,2-trifluoroacetic acid (1:1) |
| CAS号 | 1610056-01-3 |
| 分子式 | C37H56F3N9O18 |
| 分子量 | 971.9 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 1610056-01-3.mol |
| 结构式 |  |
1610056-01-3 性质
| 储存条件 | Store at -20°C |
|---|---|
| 溶解度 | 溶于二甲基亚砜 |
Peptide T (TFA) 是源自HIV-1 gp120的V2区的八肽。 Peptide T是 CD4 受体的配体，可阻止 HIV 与CD4受体结合。
CD4, HIV
Peptide T acts to block viral entry as it inhibits in the MAGI cell assay and blocks infection in the luciferase reporter assay using HIV virions pseudotyped with ADA envelope. Peptide T selectively inhibits HIV replication using chemokine receptor CCR5 compared to CXC4. Peptide T at 10 -8 M induces IL-10 production by the human Th2 cell line and PBMC. Also peptide T at 10 -9 M concentration significantly inhibits IFN-g production by PBMC.
Peptide T is administered subcutaneously at different doses and phases of the experimental autoimmune encephalomyelitis (EAE) disease, but Peptide T neither prevents nor ameliorates EAE.
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2023/03/20 | HY-P0272A | 1610056-01-3 Peptide T TFA | 1610056-01-3 | 1mg | 1000元 |
| 2023/03/20 | HY-P0272A | 1610056-01-3 Peptide T TFA | 1610056-01-3 | 5mg | 2900元 |